Top

Published in:

01-01-2020 | Solid Tumor | Original Article

The use of crevicular fluid to assess markers of inflammation and angiogenesis, IL-17 and VEGF, in patients with solid tumors receiving zoledronic acid and/or bevacizumab

Authors: Erofili Papadopoulou, Ourania Nicolatou-Galitis, Ioannis Papassotiriou, Helena Linardou, Aikaterini Karagianni, Konstantinos Tsixlakis, Anthi Tarampikou, Kelly Michalakakou, Emmanouil Vardas, Dimitrios Bafaloukos

Published in: Supportive Care in Cancer | Issue 1/2020

Abstract

Purpose

Crevicular fluid was used to assess interleukin-17 (IL-17) and vascular endothelial growth factor (VEGF) in cancer patients receiving zoledronic acid and/or bevacizumab. The markers were also assessed in the serum.

Methods

Twenty-five patients were included and comprised three groups: patients who received zoledronic acid (n = 9), patients who received bevacizumab (n = 9), and patients who received zoledronic acid combined with bevacizumab (n = 5). One patient received zoledronic acid and everolimus and another received zoledronic acid, bevacizumab, and temsirolimus. IL-17 and VEGF were measured by standard quantitative ELISA kits and assessed in two study points.

Results

Twenty-four patients maintained good periodontal health; one had asymptomatic osteonecrosis of the jaw. First assessment: 44 samples were collected; 21 from serum and 23 from crevicular fluid. Second assessment, 6 months later: 11 samples were collected; 6 from serum and 5 from crevicular fluid. IL-17 was detected in all samples, in serum and crevicular fluid, and remained unchanged at both time points. Serum VEGF in patients with bevacizumab alone or combined with zoledronic acid was significantly lower compared with that of patients who received zoledronic acid alone. VEGF was not detected in the crevicular fluid.

Conclusions

Crevicular fluid might be an easy, non-invasive means to assess IL-17. The stable values of IL-17 in crevicular fluid and serum and the lack of VEGF in the crevicular fluid could be related to the good periodontal health of our patients. Further studies are needed to assess IL-17 and VEGF in the crevicular fluid in patients with and without periodontal disease.

Yang B, Hang H, Fung A, Zhao H et al (2014) The role of interleukin 17 in tumour proliferation, angiogenesis and metastasis. Mediat Inflamm 2014:623759. https://doi.org/10.1155/2014/623759 CrossRef

Cheng WC, Hughes FJ, Taams LS (2014) The presence, function and regulation of IL-17 and Th17 cells in periodontitis. J Clin Periodontol 41:541–549. https://doi.org/10.1111/jcpe.12238 CrossRefPubMed

Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takayanagi H (2006) Th17 functions as an osteoclastogenic helper T cell subject that links T cell activation and bone destruction. J Exp Med 27(203):2673–2682. https://doi.org/10.1084/jem.20061775 CrossRef

Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird BA, Lee CS, Shnier R, Portek IJ (2006) Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 54:1122–1131. https://doi.org/10.1002/art.21749 CrossRefPubMed

Gacche RN, Meshram RJ (2013) Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth. Prog Biophys Mol Biol 113:333–354. https://doi.org/10.1016/j.pbiomolbio.2013.10.001 CrossRefPubMed

Bissachi D, Benelli R, Vanzetto C et al (2003) Anti-angiogenesis and angioprevention: mechanisms, problems and perspectives. Cancer Detect Prev 27:229–238CrossRef

Nicolatou-Galitis O, Razis E, Galiti D, Galitis E, Labropoulos S, Tsimpidakis A, Sgouros J, Karampeazis A, Migliorati C (2015) Periodontal disease preceding osteonecrosis of the jaw (ONJ) in cancer patients receiving aniresorptives alone or combined with targeted therapies: report of 5 cases and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol 120:699–706. https://doi.org/10.1016/j.oooo.2015.08.007 CrossRefPubMed

Tsao C, Darby I, Ebeling P, Walsh K et al (2013) Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J Oral Maxillofac Surg 71:1360–1366. https://doi.org/10.1016/j.joms.2013.02.016 CrossRefPubMed

Vincenzi B, Napolitano A, Zoccoli A, Iuliani M, Pantano F, Papapietro N, Denaro V, Santini D, Tonini G (2012) Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw. J Hematol Oncol 5:56. https://doi.org/10.1186/1756-8722-5-56 CrossRefPubMedPubMedCentral

10.

Subrahmanyaam MV, Sangyeetha M (2003) Gingival crevicular fluid a marker of the periodontal disease activity. Indian J Clin Biochem 18:5–7. https://doi.org/10.1007/BF02867658 CrossRef

11.

Longo PL, Artese HPC, Horliana ACRT, Gomes GH, Ramito GA et al (2015) Inflammatory markers in gingival crevicular fluid of periodontitis patients with type 2 diabetes mellitus according to glycerine control: a pilot study. Dent Res J (Isfahan) 12:449–455CrossRef

12.

Noonan K, Marchionni L, Anderson J, Pardoll D, Roodman GD, Borrello I (2010) A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 116:3554–3563. https://doi.org/10.1182/blood-2010-05-283895 CrossRefPubMedPubMedCentral

13.

Luo Z, Wang H, Chen J, Kang J, Sun Z, Wu Y (2015) Overexpression and potential regulatory role of IL-17F in pathogenesis of chronic periodontitis. Inflammation 38:978–986. https://doi.org/10.1007/s10753-014-0060-6 CrossRefPubMed

14.

Zenobia C, Hajishengallis G (2015) Basic biology and role of interleukin-17 in immunity and inflammation. Periodontol 69:142–159. https://doi.org/10.1111/prd.12083. CrossRef

15.

Ajuz N, Antunes H, Mendonca T, Pires F et al (2014) Immunosuppression of interleukin-17 in apical periodontitis lesions. JOE 40:1400–1403. https://doi.org/10.1016/j.joen.2014.03.024 CrossRefPubMed

16.

Kikuiri T, Kim I, Yamaza T, Akiyama K, Zhang Q, Li Y, Chen C, Chen WJ, Wang S, le AD, Shi S (2010) Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice. J Bone Miner Res 25:1668–1679. https://doi.org/10.1002/jbmr.37 CrossRefPubMedPubMedCentral

17.

Zhang Q, Atsuta I, Liu S, Chen C, Shi S, Shi S, le AD (2013) IL-17-mediated M1/M2 macrophage alteration contributes to pathogenesis of bisphosphonate-related osteonecrosis of the jaws. Clin Cancer Res 19:3176–3188. https://doi.org/10.1158/1078-0432.CCR-13-0042 CrossRefPubMedPubMedCentral

18.

Rosella D, Papi P, Giardino R, Cicalini E, Piccoli L, Pompa G (2016) Medication-related osteonecrosis of the jaw: clinical and practical guidelines. J Int Soc Prev Community Dent 6:97–104. https://doi.org/10.4103/2231-0762.178742 CrossRefPubMedPubMedCentral

19.

Nicolatou-Galitis O, Papadopoulou E, Sarri T, Boziari P, Karayianni A, Kyrtsonis MC, Repousis P, Barbounis V, Migliorati CA (2011) Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112:195–202. https://doi.org/10.1016/j.tripleo.2011.02.037 CrossRefPubMed

20.

Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, Migkou M, Eleftherakis-Papaiakovou E, Christoulas D, Terpos E, Bamias A (2009) Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20:117–120. https://doi.org/10.1093/annonc/mdn554 CrossRefPubMed

21.

Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, Bareggi C, Ascani L, Cislaghi E (2009) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20:137–145. https://doi.org/10.1093/annonc/mdn526 CrossRefPubMed

22.

Vladau M, Cimpean AM, Balica RA, Jitariu AA, Popovici RA, Raica M (2016) VEGF/VEGFR2 Axis in periodontal disease progression and angiogenesis: basic approach for a new therapeutic strategy. In Vivo 30:53–60PubMed

23.

Padma R, Anaji S, Indeevar P, Indranil S, Chetan SK (2014) Vascular endothelial growth factor levels in gingival crevicular fluid before and after periodontal therapy. J Clin Diagn Res 8:75–79

24.

Prapulla DV, Sujatha PB, Pradeep AR (2007) Gingival crevicular fluid VEGF levels in periodontal health and disease. J Periodontol 78:1783–1787. https://doi.org/10.1902/jop.2007.070009 CrossRefPubMed

25.

Santini D, Vincenzi B, Battistoni F et al (2007) In vivo perspective study about the effects of weekly low dose administration of zoledronic acid (ZA) on angiogenesis. J Clin Oncol 25(suppl):152

26.

Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V, Tocchini M, Bonsignori M, Tonini G (2003) ZA induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9:2893–2897PubMed

27.

Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E (2008) Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases. Med Oncol 25:346–349. https://doi.org/10.1007/s12032-008-9043-5 CrossRefPubMed

28.

Thumbigere-Math V, Michalowicz B, Hughes PJ, Basi DL et al (2016) Serum markers of bone turnover and angiogenesis in bisphosphonate-related osteonecrosis of the jaw patients following discontinuation of long-term intravenous bisphosphonate therapy. J Oral Maxillofac Surg 74(4):738–746. https://doi.org/10.1016/j.joms.2015.09.028 CrossRefPubMed

Title: The use of crevicular fluid to assess markers of inflammation and angiogenesis, IL-17 and VEGF, in patients with solid tumors receiving zoledronic acid and/or bevacizumab
Authors: Erofili Papadopoulou
Ourania Nicolatou-Galitis
Ioannis Papassotiriou
Helena Linardou
Aikaterini Karagianni
Konstantinos Tsixlakis
Anthi Tarampikou
Kelly Michalakakou
Emmanouil Vardas
Dimitrios Bafaloukos
Publication date: 01-01-2020
Publisher: Springer Berlin Heidelberg
Keywords: Solid Tumor
Osteonecrosis
Bevacizumab
Zoledronic Acid
Everolimus
mTOR-Inhibitors
Published in: Supportive Care in Cancer / Issue 1/2020
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-019-04793-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Examination of referral criteria for outpatient palliative care among patients with advanced cancer

Patterns of primary health care service use of Indigenous Australians diagnosed with cancer

Health-related and cancer-related Internet use by patients treated with total laryngectomy

Patient-reported outcomes of the relative severity of side effects from cancer radiotherapy

Demographic, medical, social-cognitive, and environmental correlates of meeting independent and combined physical activity guidelines in kidney cancer survivors

Assessing quality of life in palliative care settings: head-to-head comparison of four patient-reported outcome measures (EORTC QLQ-C15-PAL, FACT-Pal, FACT-Pal-14, FACT-G7)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer